admitted between November, 2005, and October, 2006 for measurement of circulating endothelial progenitor cell levels after acute IS (supported by a grant from the National Science Council, Taiwan, ROC, Grant No. NSC 94-2314-B-182A-197). Thus, the present study included 217 acute IS patients.
Stroke was defined as sudden onset of loss of global or focal cerebral function that persisted for more than 24 h. The origin of cerebral ischemia was classified according to the Trial of Org 10172 in the Acute Stroke Treatment (TOAST) criteria. 21 To limit the factors affecting the circulating level of IL-18, we excluded patients with intracranial hemorrhage, a history of recent surgery or trauma during the preceding 2 months, renal insufficiency (creatinine >1.5 mg/dl), malignancy, febrile disorders, acute or chronic inflammatory disease at study enrollment, autoimmune diseases with or without immunosuppressive therapy, or a prior myocardial infarction onset <3 months, as well as those with a history of atrial fibrillation, valvular heart disease, or intracardiac thrombus on echocardiograph.
Forty subjects matched for age, gender, hypertension, diabetes mellitus, current smoking and hypercholesterolemia were assigned to the at-risk control group. Additionally, 20 age-and gender-matched healthy volunteers were assigned to the healthy control group. Informed consent was given by each study subject. The Institutional Review Committee on Human Research approved the study protocol.
Blood Sampling and Laboratory Investigations
For the purpose of this study, blood samples for plasma IL-18 levels of patients who were admitted to hospital were prospectively drawn from the antecubital vein into EDTA tubes at 48 h after acute IS. Blood samples were obtained once in both the healthy volunteers after healthy clinic examination, and the at-risk control subjects from the outpatient department. After centrifugation, aliquots of the samples were immediately stored at -80°C before assay for IL-18. White blood cell (WBC) count and biochemical measurements were done using standard laboratory methods.
Plasma IL-18 level was measured by duplicated determination with a commercially available ELISA method (B & D). The analytical range extended from 5 to 5,000 pg/ml. Intra-individual variability of IL-18 levels was assessed in the study patients and both control groups. The mean intraassay coefficients of variance were all less than 4.0%.
Neurological Assessment
The physical and social functions of stroke patients were evaluated using the modified Rankin Scale score 22 during the acute, convalescence and chronic phases of stroke
Imaging Studies and Laboratory Investigations
In additional to a full clinical assessment, ancillary examinations were performed, including WBC count, biochemical data, chest X-ray, routine brain computed tomography (CT) and magnetic resonance imaging (MRI)/magnetic resonance angiography, duplex scanning of the carotid arteries, and routine cardiac analysis by 12-lead electrocardiography and echocardiography.
Medications
Aspirin was the first choice for acute IS patients unless 
Definitions and 90-Day Composite Endpoints
The study endpoint was the 90-day composite occurrence of major adverse clinical outcomes (MACO), including recurrent stroke or mortality. Recurrent stroke was defined as another episode of sudden onset of loss of global or focal cerebral function that persisted for more than 24 h, occurring either during hospitalization or after discharge. The recurrent stroke was further confirmed by neurological examination, CT scan and MRI. Mortality was defined as any cause of death within 90 days after the first IS.
Statistical Analysis
Data are expressed as mean ± SD. Categorical variables were compared using chi-square or Fischer exact test. Continuous variables between 2 groups were analyzed by the Wilcoxon rank sum test. Continuous variables among 3 groups were analyzed by 1-way ANOVA or Kruskal-Wallis test followed by the multiple comparison procedure by Wilcoxon rank sum test and Bonferroni correction. Discriminate analysis was employed to find out a cut-off value of IL-18 level that was the most significant value with good sensitivity and specificity for predicting 90-day MACO. Statistical analysis was performed using SAS statistical software for Windows version 8.2 (SAS institute, Cary, NC, USA). A value of p<0.05 was considered statistically significant. (Table 1) There was neither a significant difference among the 3 groups for age, gender and creatinine level, nor between IS patients and at-risk control subjects for coronary artery disease risk factors. Additionally, the incidence of statin and ACEI/ARB treatment did not differ between IS patients and at-risk control subjects. However, the WBC counts and IL-18 levels were significantly higher in IS patients than in either group of controls. Moreover, the IL-18 level was significantly higher in the at-risk controls than in the healthy controls. The incidence of stroke etiologic subtype was higher for the non-lacunar type than for the lacunar type. Additionally, the IL-18 level was significantly higher in (1,047.9±839.8 vs 424.9±284.2, p<0.001). The 90-day cumulative death and recurrent stroke rates in the IS patients were 8.8% and 3.2%, respectively. (Table 2 ) The plasma IL-18 level of ≥780 pg/ml was the most powerful cut-off value identified using the discriminating test for predicting 90-day MACO, with a sensitivity of 91.3% and a specificity of 76.0%. Thus, patients with plasma IL-18 levels ≥780 pg/ml were classified as the high IL-18 level group (Group 1), and those with plasma IL-18 levels <780 pg/ml were assigned to the low IL-18 level group (Group 2). The 2 groups did not significantly differ in age, gender, hypertension, smoking status, hypercholesterolemia, previous stroke, creatinine level, or incidence of statin or ACEI/ARB therapy. However, the incidence of both diabetes mellitus and coronary artery disease (proven by previous coronary angiographic study) was significantly higher in Group 1 than in Group 2 patients. Additionally, the circulating level of IL-18 and the WBC count were substantially higher in Group 1 than in Group 2 patients. Moreover, Group 1 patients had notably higher rates of 90-day recurrent stroke and 90-day mortality than Group 2 patients. Furthermore, the 90-day composite occurrence of MACO was remarkably higher in Group 1 than in Group 2 patients. 
Results
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Determinants of 30-Day Composite MACO (Table 3)
The most significant factor among these variables was high IL-18 level (≥780 pg/ml). The WBC count, coronary artery disease, creatinine level, modified Rankin scale score and coronary artery disease were also significantly related to increased incidence of 90-day MACO.
Multiple stepwise logistic regression analysis of all univariate significant factors shown in Table 4 showed that high IL-18 level (≥780 pg/ml) was the most independent predictor of 90-day MACO. Additionally, the creatinine level was also independently predictive of 90-day MACO. Moreover, after adjusting for neurological severity, the IL-18 level was still independently predictive of 30-day MACO.
Correlation analysis by Spearman test demonstrated that increased circulating levels of IL-18 was significantly related to increased modified Rankin scale score upon presentation (at 48 h) (r=0.759, p<0.0001) (Fig 1) . Additionally, increased circulating levels of IL-18 upon presentation strongly correlated with increased 90-day modified Rankin scale score (r=0.540, p<0.0001).
Discussion
Examination of the circulating level of IL-18 and relevant clinical variables in acute IS patients in this study produced several important clinical implications. First, IL-18, a newly discovered pro-inflammatory cytokine, was present in significantly higher levels in acute IS patients than in either at-risk controls or normal controls. Second, 90-day mortality in patients with a high circulating IL-18 level was more than 37-fold higher than that of patients with a low circulating IL-18 level. Third, a strong independent association was observed between increasing IL-18 level and 90-day MACO after acute IS.
Previous studies have demonstrated that IL-18 acts as a pro-inflammatory cytokine 14 by directly inducing IL-1 and IL-8, 8, 10 as well as the expression of adhesion molecules. 23 The IL-18 cytokine also stimulates the production of granulocyte-macrophage colony-stimulating factor, tumor necrotic factor-, and inducible nitric oxide synthetase by mononuclear and mesenchymal cells. 14 Surprisingly, considering the potent inflammatory activities of IL-18, 4, 10, 13, 16, 17 and the strong association of circulating IL-18 level with prognostic outcomes in patients with and without cardiovascular disease, 18, 19 as well as in patients with acute myocardial infarction (AMI) undergoing primary coronary angioplasty, 24 data addressing the prognostic value of the circulating level of IL-18 in acute IS patients is unavailable. To the best of our knowledge, the present study is the largest and the first cohort study to evaluate the impact of the circulating level of IL-18 in patients following acute IS. An important finding of this study was that the plasma level of IL-18 was substantially higher in IS patients than in at-risk or normal control subjects. This finding supports the finding from a previous study 20 and suggests that IL-18 also contributes to the inflammatory process in the clinical setting of acute IS, 20 in addition to the clinical settings of AMI 24 and cardiovascular disease. 18 Another important finding was the good correlation between the circulating level of IL-18 and modified Rankin scale score on presentation and on day 90 after IS. The link between the serum level of IL-18 and neurological stoke severity and functional disability documented in the present study is supported by a previous study. 20 Whether IL-18 directly participates in cerebrovascular ischemia and/or brain injury or is only a biomarker of systemic inflammation in IS patients remains uncertain. Recent reports have examined the impact of IL-18 level on carotid artery atherosclerosis. Additionally, experimental studies have shown that IL-18 is intimately related to atherosclerotic plaque propagation and instability. 4, 16, 17 Moreover, an experimental study had previously demonstrated that IL-18 is involved in hypoxic-ischemic brain injury. 9 Therefore, the evidence from the present study and those previous studies 4, 16, 17 suggests that IL-18 is involved in brain injury either indirectly, by causing inflammation in the brain 20 or by atherothrombosis of the cerebral macro-and/or micro-vasculature, or directly by enhancing the cytotoxic activity of immune cells. In addition, the rapid and marked increase in the circulating level of IL-18 in the present patients was mainly because of the brain injury following acute IS, which then mediated an acute inflammatory response, and was clinically identified as neurological impairment. A previous study 20 suggested that IL-18 is involved in stroke-induced inflammation. The cumulative evidence from our clinical and laboratory findings, as well as from the previous study, 20 suggests that IL-18 increase in the serum of acute IS patients results, at least in part, from cytokine leakage from infarct blood or from cerebrospinal fluid into the systemic circulation.
Studies have previously demonstrated that the plasma concentration of IL-6, a pro-inflammatory cytokine, is independently predictive of prognostic outcome after IS. 25, 26 Additionally, an association between C-reactive protein (CRP) or high-sensitivity (hs)-CRP and untoward clinical outcomes following acute IS has been well established. [27] [28] [29] In the present study, the most important finding was the independent predictive value of an increased circulating level of IL-18 for 90-day MACO. Recently, we have demonstrated that the IL-18 level is one of the most reliable independent predictors of 30-day MACO in patients with AMI undergoing primary coronary angioplasty. 24 Accordingly, the results observed in the present study concur with those of previous studies, 4, [16] [17] [18] [19] as well as our recent study, 24 and further document the participation of pro-inflammatory cytokines in the inflammatory responses in both cardiovascular 24 and cerebrovascular disease. 27 Therefore, our findings further support those of previous studies 25- 29 and we suggest that certain inflammatory mediators, especially the level of circulating IL-18, should be examined to predict the clinical outcome in patients following acute IS.
Patients who had renal insufficiency (creatinine >1.5 mg/dl) were excluded and, surprisingly, the creatinine level was independently predictive of 90-day MACO. An association between creatinine level and poor prognostic outcome in patients with coronary artery disease undergoing coronary angioplasty has been reported, 30, 31 which is consistent with our impression.
Study Limitations
First, without serial measurement of the circulating IL-18 levels, this study yielded no data regarding when and how long IL-18 is elevated in these patients. However, a previous study already demonstrated that the serum level of IL-18 rapidly increased after acute IS and decreased to a normal level 3 weeks later. 20 Second, the effects of circulating IL-18 on long-term clinical outcome were not included in the study protocol, so these relationships were not examined beyond the 90-day clinical outcome. Finally, previous studies [25] [26] [27] [28] [29] have shown that IL-6, a pro-inflammatory, and hs-CRP, an index of inflammation, are strongly associated with the prognostic outcome after IS. Without measuring the circulating levels of either of these in this study and comparing these 2 inflammatory markers with IL-18, we remain uncertain which inflammatory marker is the most independently predictive of clinical outcome in patients after IS.
Conclusion
This study demonstrated that the circulating level of IL-18 is substantially increased in acute IS patients and it is suggested that this can be used as a reliable biomarker of the inflammatory process in acute IS patients. Additionally, a high circulating IL-18 level (≥780 pg/ml) on admission is strongly associated with increased 90-day MACO. These findings support the use of the circulating IL-18 level for risk stratification of patients after acute IS.
